☆ 4.7 Review

New-onset and relapsed thrombotic microangiopathy post-COVID-19 vaccination

JOURNAL OF MEDICAL VIROLOGY (2023)

Related references

Note: Only part of the references are listed.

Letter Hematology

Acquired Thrombotic Thrombocytopenic Purpura: A Rare Coincidence after COVID-19 mRNA Vaccine?

Allison C. Y. Tso et al.

SEMINARS IN THROMBOSIS AND HEMOSTASIS (2023)

Add to Collection

Review Medicine, General & Internal

Concurrence of immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura: a case report and review of the literature

Hung-Chen Lin et al.

Summary: This article reports a rare case of concurrent immune thrombocytopenic purpura and thrombotic thrombocytopenic purpura in a 32-year-old Asian female. Glucocorticoid treatment increased the platelet count, but schistocytes remained high. Further investigations revealed deficiency in ADAMTS13 activity and positive ADAMTS13 antibodies. Plasma exchange therapy showed good response and maintained normal platelet count.

JOURNAL OF MEDICAL CASE REPORTS (2023)

Add to Collection

Article Urology & Nephrology

Atypical Hemolytic Uremic Syndrome Occurring After Receipt of mRNA-1273 COVID-19 Vaccine Booster: A Case Report

Kathleen J. Claes et al.

Summary: We report a case of a previously healthy 38-year-old woman who developed atypical hemolytic uremic syndrome (aHUS) after receiving a booster dose of an mRNA COVID-19 vaccine. The patient experienced symptoms of headache, nausea, and general malaise, and was diagnosed with thrombotic microangiopathy (TMA). Treatment included blood pressure control, hemodialysis, plasma exchange, and respiratory support, and kidney function improved with the initiation of eculizumab therapy. Genetic analysis identified a pathogenic variant in complement C3. Based on the timing, we hypothesize that the vaccine was likely the trigger for aHUS development in this patient.

AMERICAN JOURNAL OF KIDNEY DISEASES (2023)

Add to Collection

Review Urology & Nephrology

Renal Thrombotic Microangiopathy: A Review

Dominique Suzanne Genest et al.

Summary: Thrombotic microangiopathy (TMA) is a common pathological lesion caused by endothelial injury and dysfunction. Renal-limited forms of TMA are not uncommon and often pose diagnostic challenges. Prompt investigation and treatment are important to reduce morbidity and mortality. Advances in understanding the pathophysiology of TMA have led to the development of diagnostic tools and targeted therapies. This article reviews the clinical presentation, pathologic hallmarks, and treatment strategies for TMA involving the kidney.

AMERICAN JOURNAL OF KIDNEY DISEASES (2023)

Add to Collection

Article Immunology

End-Stage Kidney Disease Resulting from Atypical Hemolytic Uremic Syndrome after Receiving AstraZeneca SARS-CoV-2 Vaccine: A Case Report

Mohammed Tawhari et al.

Summary: Hemolytic uremic syndrome (HUS) is characterized by nonimmune hemolytic anemia, thrombocytopenia, and acute kidney injury. Atypical HUS (aHUS) is a rare variant associated with genetic or acquired dysregulation of the alternative complement pathway. In this case report, a 38-year-old male developed aHUS after receiving the first dose of AstraZeneca SARS-CoV-2 vaccine, leading to microangiopathic hemolytic anemia and severe kidney impairment. Treatment with plasma exchange, prednisone, and rituximab resulted in improvement of hematological parameters, but the patient progressed to end-stage kidney disease (ESKD).

VACCINES (2023)

Add to Collection

Article Urology & Nephrology

Semi-selective plasma filtration applied to the treatment of acquired thrombotic thrombocytopenic purpura following bnt162b2 administration

Roberta Fenoglio et al.

Summary: A case of thrombocytopenia and microangiopathic hemolytic anemia following vaccination with bnt162b2 was reported, and the treatment process using medications and methods was described.

JOURNAL OF NEPHROLOGY (2023)

Add to Collection

Letter Hematology

ChAdOx1 nCov-19 vaccine-induced thrombotic thrombocytopenic purpura successfully treated with plasmapheresis

Yen-Ching Wang et al.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Letter Hematology

First report of COVID-19 vaccine induced flare of compensated congenital thrombotic thrombocytopenic purpura

Kaitlyn C. Dykes et al.

BLOOD COAGULATION & FIBRINOLYSIS (2022)

Add to Collection

Article Medicine, General & Internal

Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient

Kikuaki Yoshida et al.

Summary: This article reports the first Japanese case of TTP possibly associated with vaccination. The patient developed severe hematological complications after receiving the COVID-19 vaccine. Combination therapy with plasma exchange, corticosteroid, and rituximab improved the clinical outcome.

INTERNAL MEDICINE (2022)

Add to Collection

Letter Hematology

Immune Thrombotic Thrombocytopenic Purpura following Pfizer-BioNTech anti-COVID-19 vaccination in a patient healed from lymphoma after allogeneic hematopoietic stem cell transplantation

Vanessa Innao et al.

THROMBOSIS RESEARCH (2022)

Add to Collection

Letter Hematology

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine

Tekin Guney et al.

TURKISH JOURNAL OF HEMATOLOGY (2022)

Add to Collection

Article Immunology

New-Onset Kidney Diseases after COVID-19 Vaccination: A Case Series

Jeong-Hoon Lim et al.

Summary: This study reports the clinical courses and histopathologic findings of new-onset kidney diseases after COVID-19 vaccination. The specific types of kidney diseases identified include IgA nephropathy, minimal change disease, thrombotic microangiopathy, and acute tubulointerstitial nephritis. Individualized treatment improved the outcomes of all patients. Clinicians should consider the possibility of vaccine-induced kidney diseases in patients with renal symptoms.

VACCINES (2022)

Add to Collection

Letter Urology & Nephrology

Minimal change disease with thrombotic microangiopathy following the Pfizer-BioNTech COVID-19 vaccine

Fumika Tanaka et al.

CLINICAL KIDNEY JOURNAL (2022)

Add to Collection

Letter Hematology

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine

Johannes Ruhe et al.

ANNALS OF HEMATOLOGY (2022)

Add to Collection

Letter Hematology

Thrombotic thrombocytopenic purpura temporally associated with BNT162b2 vaccination in an adolescent successfully treated with caplacizumab

Amrit Kirpalani et al.

BRITISH JOURNAL OF HAEMATOLOGY (2022)

Add to Collection

Article Hematology

Immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

Adrien Picod et al.

BLOOD (2022)

Add to Collection

Editorial Material Hematology

Immune-mediated thrombotic thrombocytopenic purpura following administration of Pfizer-BioNTech COVID-19 vaccine

Gaetano Giuffrida et al.

HAEMATOLOGICA (2022)

Add to Collection

Article Hematology

Complement dysregulation is associated with severe COVID-19 illness

Jia Yu et al.

Summary: The serum of COVID-19 patients can induce complement-mediated cell death and is associated with dysregulation of APC, which may contribute to the pathogenesis and severity of the disease.

HAEMATOLOGICA (2022)

Add to Collection

Editorial Material Hematology

Thrombotic thrombocytopenic purpura and other immune-mediated blood disorders following vaccination against SARS-CoV-2

Pier Mannuccio Mannucci

HAEMATOLOGICA (2022)

Add to Collection

Article Hematology

Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study

Gaetano Giuffrida et al.

Summary: This study evaluated the effects of mRNA COVID-19 vaccination in adult patients with iTTP. Five out of 32 patients experienced a biochemical relapse after vaccination, highlighting the potential for iTTP relapse following COVID-19 vaccination. Despite the risks, the benefits of vaccination outweigh the potential risks.

HAEMATOLOGICA (2022)

Add to Collection

Article Hematology

Refractory immune TTP following Pfizer-BioNTech COVID-19 vaccine successfully salvaged with caplacizumab

Eva Laverdure et al.

Summary: This case report describes a young healthy female who developed immune thrombotic thrombocytopenic purpura (iTTP) after receiving the Pfizer Bio-NTech COVID-19 vaccine. Despite initial response to standard treatment, she experienced acute deterioration with neurological and cardiac involvement. However, she had a prompt response to rituximab and caplacizumab and achieved remission.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Review Medical Laboratory Technology

Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature Review

Emna Hammami et al.

Summary: Thrombotic thrombocytopenic purpura (TTP) is a deadly thrombotic microangiopathy that can be treated with plasma exchanges. The occurrence of TTP after COVID-19 vaccination is rare but should be taken seriously.

LABORATORY MEDICINE (2022)

Add to Collection

Article Infectious Diseases

Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe

Hannah G. Rosenblum et al.

Summary: The surveillance data from the first 6 months of the US COVID-19 vaccination program, involving over 298 million doses of mRNA vaccines, demonstrate that the majority of reported adverse events were mild and of short duration.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Oncology

COVID-19 vaccine (mRNA BNT162b2) and COVID-19 infection-induced thrombotic thrombocytopenic purpura in adolescents

Luna Vorster et al.

Summary: The mRNA COVID-19 vaccine and COVID-19 infection may trigger the development of thrombotic thrombocytopenic purpura (TTP), but there is limited literature on the subject in pediatric or adolescent patients. This study describes three adolescents who developed TTP, either as newly diagnosed or relapsed cases, after receiving the Pfizer COVID-19 vaccine or contracting COVID-19. The findings suggest that both the Pfizer-BioNTech mRNA vaccine and COVID-19 infection can act as triggers for the development or relapse of both congenital and acquired TTP.

PEDIATRIC BLOOD & CANCER (2022)

Add to Collection

Review Hematology

Thrombotic thrombocytopenic purpura (TTP) after COVID-19 vaccination: A systematic review of reported cases

Prachi Saluja et al.

Summary: With the advent of COVID-19 vaccines, there have been reports of autoimmune hematological complications such as TTP occurring after vaccination. This study reviewed existing cases of TTP after COVID-19 vaccination and found that it is more common after BNT162b2 and mRNA-1273 vaccines. Treatment for immune TTP typically involves plasma exchange and steroids. An in-depth anamnesis before vaccination is important, and the possibility of TTP should be considered when evaluating post-vaccine thrombocytopenia.

THROMBOSIS RESEARCH (2022)

Add to Collection

Article Medicine, General & Internal

Immune-Mediated Thrombotic Thrombocytopenic Purpura Following mRNA-Based COVID-19 Vaccine BNT162b2: Case Report and Mini-Review of the Literature

Vanessa Alexandra Buetler et al.

Summary: This article presents a case of iTTP following COVID-19 vaccination and reviews previously reported cases. The findings suggest a potential association between COVID-19 vaccination and iTTP.

FRONTIERS IN MEDICINE (2022)

Add to Collection

Letter Urology & Nephrology

First case of atypical haemolytic uraemic syndrome following COVID-19 vaccination with BNT162b2

Sophie H. Schmidt et al.

CLINICAL KIDNEY JOURNAL (2022)

Add to Collection

Article Multidisciplinary Sciences

Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom

Edward Burn et al.

Summary: Population-based studies can provide important evidence on the safety of COVID-19 vaccines. In this study, the authors compared the rates of thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in the United Kingdom with the background (expected) rates in the general population.

NATURE COMMUNICATIONS (2022)

Add to Collection

Article

Coincidental or causal? A case report of acquired thrombotic thrombocytopenic purpura following mRNA-1273 Covid-19 vaccination

Erinie M Mekheal et al.

Hematology Transfusion and Cell Therapy (2022)

Add to Collection

Review Immunology

Acquired Thrombotic Thrombocytopenic Purpura Following Inactivated COVID-19 Vaccines: Two Case Reports and a Short Literature Review

Imen Ben Saida et al.

Summary: This is the first report of acquired TTP after inactivated virus COVID-19 vaccination, and the patients recovered after treatment with corticosteroids, plasma exchange therapy, and rituximab.

VACCINES (2022)

Add to Collection

Article Medicine, General & Internal

Recurrence of Thrombotic Thrombocytopenic Purpura After Vaccination with mRNA-1273 COVID-19 vaccine

Spyridon Ntelis et al.

Summary: Thrombotic thrombocytopenic purpura (TTP) is a rare disease associated with COVID-19 vaccine administration. Early recognition and timely treatment are crucial for preventing complications. We report a case of TTP following COVID-19 vaccination and highlight the importance of prompt intervention.

JOURNAL OF COMMUNITY HOSPITAL INTERNAL MEDICINE PERSPECTIVES (2022)

Add to Collection

Article Medicine, General & Internal

Relapse of immune thrombotic thrombocytopenic purpura (iTTP) possibly triggered by COVID-19 vaccination and/or concurrent COVID-19 infection

Fei Fang et al.

Summary: This study reports a case of relapsed immune thrombotic thrombocytopenic purpura (iTTP) in a patient who received Moderna mRNA-1273 SARS-CoV-2 vaccine and also developed severe COVID-19 infection. The authors summarize published cases of iTTP associated with COVID-19 infection or vaccination.

BMJ CASE REPORTS (2022)

Add to Collection

Review Virology

New-Onset and Relapsed Membranous Nephropathy post SARS-CoV-2 and COVID-19 Vaccination

Qiqi Ma et al.

Summary: This article reports five cases of membranous nephropathy (MN) associated with SARS-CoV-2 infection and 37 cases related to COVID-19 vaccination. Most patients showed positive response to conventional immunosuppressive drugs and rituximab. Conservative treatment was effective for newly diagnosed patients. The mechanisms of MN post COVID-19 vaccination might involve cross immunity and enhanced immune response.

VIRUSES-BASEL (2022)

Add to Collection

Article Immunology

Atypical hemolytic uremic syndrome triggered by mRNA vaccination against SARS-CoV-2: Case report

Romana Rysava et al.

Summary: Atypical hemolytic uremic syndrome (aHUS) is a rare disease caused by dysregulation in the alternative complement activation pathway. It is a life-threatening condition that typically causes acute kidney injury. Genetic mutations and factors like viral or bacterial infections can trigger the disease, and eculizumab is an effective treatment method.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Immunology

COVID-19 vaccination and Atypical hemolytic uremic syndrome

Romy N. Bouwmeester et al.

Summary: COVID-19 vaccination has been associated with the development of atypical hemolytic uremic syndrome (aHUS) in some patients, but the overall risk is limited. It is recommended to continue vaccination in patients with a previous episode of aHUS, with clear instructions on how to recognize symptoms of recurrence.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation

Ting Gao et al.

Summary: This study found that the N proteins of highly pathogenic human coronaviruses can bind to MASP-2, resulting in excessive complement activation and inflammatory lung injury. Blocking the interaction between the N protein and MASP-2 or suppressing complement activation can alleviate virus-induced lung injury.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Add to Collection

Article Hematology

Clinical relapse of immune-mediated thrombotic thrombocytopenic purpura following COVID-19 vaccination

William Deucher et al.

Summary: This case report describes a relapse of immune-mediated thrombotic thrombocytopenic purpura (iTTP) following COVID-19 vaccination. The patient, a 28-year-old woman, had a previous diagnosis of iTTP and was in clinical remission before receiving the vaccine. Shortly after vaccination, she experienced symptoms of thrombocytopenia and schistocytes, but achieved complete remission after treatment. The report highlights the need for caution when administering COVID-19 vaccines to iTTP survivors with severely deficient ADAMTS-13 activity.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Urology & Nephrology

Atypical Hemolytic Uremic Syndrome after ChAdOx1 nCoV-19 Vaccination in a Patient with Homozygous CFHR3/CFHR1 Gene Deletion

Francisco Ferrer et al.

Summary: Hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy affecting the kidneys, while atypical HUS involves genetic or acquired dysregulation of the complement alternative pathway. The patient in the case experienced symptoms after vaccination with ChAdOx1 nCoV-19, leading to a clinical presentation of aHUS.

NEPHRON (2022)

Add to Collection

Article Hematology

Recurrence of Thrombotic Thrombocytopenic Purpura after mRNA-1273 COVID-19 Vaccine Administered Shortly after COVID-19

Korin Karabulut et al.

Summary: Thrombotic thrombocytopenic purpura (TTP) is a potential life-threatening consumptive coagulopathy, and recent COVID-19 infection and COVID-19 vaccine administration may contribute to TTP recurrence. Vaccine distribution to a larger population could lead to an increase in adverse event reporting, and this case report highlights potential safety issues with new vaccine administration in patients with recent COVID-19 and underlying autoimmune disease.

CASE REPORTS IN HEMATOLOGY (2021)

Add to Collection

Review Urology & Nephrology

Immunity, endothelial injury and complement-induced coagulopathy in COVID-19

Luca Perico et al.

Summary: This review provides insights into the pathogenic mechanisms and clinical manifestations of COVID-19, highlighting the critical role of the immunological hyper-response induced by SARS-CoV-2 infection. The authors emphasize the importance of early diagnosis and intervention in controlling disease progression.

NATURE REVIEWS NEPHROLOGY (2021)

Add to Collection

Review Immunology

COVID-19 associated thrombotic thrombocytopenic purpura (TTP) ; A case series and mini-review

Hamed Azhdari Tehrani et al.

Summary: This study reported four cases of COVID-19 patients presenting with symptoms of TTP, with peripheral blood smears showing numerous schistocytes, low ADAMTS13 antigen activity level and elevated antibody level, and positive COVID-19 PCR tests for all patients.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Review Immunology

Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections

M. Kathryn Liszewski et al.

Summary: Membrane cofactor protein CD46 plays a crucial role as a complement regulatory protein, but also functions in human reproduction, autophagy, T cell modulation, and as a receptor for pathogens. Deficiencies in CD46 contribute to inflammatory disorders, while its overexpression in cancers and as a receptor for viruses has implications in targeted therapies.

CURRENT OPINION IN IMMUNOLOGY (2021)

Add to Collection

Letter Urology & Nephrology

Atypical HUS relapse triggered by COVID-19

Simon Ville et al.

KIDNEY INTERNATIONAL (2021)

Add to Collection

Article Pharmacology & Pharmacy

Endothelial cells and SARS-CoV-2: An intimate relationship

Lucas Cunha Barbosa et al.

Summary: ACE2 plays a crucial role in regulating the renin-angiotensin-aldosterone system (RAAS) and acts as an entry receptor for SARS-CoV-2 on endothelial cells. The dysfunction of endothelial cells, triggered by factors such as cytokines, hypoxia, and complement activation, may lead to abnormal coagulation and inflammation, contributing to poor prognosis in COVID-19 patients. Endothelial cell-associated therapies, including anticoagulants and immunomodulators, have been proposed to treat COVID-19.

VASCULAR PHARMACOLOGY (2021)

Add to Collection

Review Virology

Role of Toll-like receptors in the pathogenesis of COVID-19

Shaghayegh Khanmohammadi et al.

Summary: COVID-19 caused by SARS-CoV-2 has led to a pandemic. TLRs play a crucial role in activating the immune system in response to the virus, and could potentially be a target for controlling the infection. Understanding the mechanisms of TLR in COVID-19 may help in developing vaccines and treatments.

JOURNAL OF MEDICAL VIROLOGY (2021)

Add to Collection

Article Urology & Nephrology

First diagnosis of thrombotic thrombocytopenic purpura after SARS-CoV-2 vaccine - case report

Bilgin Osmanodja et al.

Summary: This case describes a 25-year-old male patient developing aTTP after receiving the mRNA-based Spikevax vaccine. Despite presenting symptoms 13 days post-vaccination, the patient's condition improved with treatment, suggesting the vaccine may have acted as a trigger for underlying TTP.

BMC NEPHROLOGY (2021)

Add to Collection

Article Emergency Medicine

Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination

Andrew Yocum et al.

Summary: The FDA approved Johnson & Johnson's COVID-19 vaccine which uses traditional virus-based technology. Independent reports of blood clotting after COVID-19 vaccination have been documented in the US and UK, with all cases in the US being female and symptoms occurring between six to thirteen days post-vaccination.

AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)

Add to Collection

Letter Hematology

Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine

Cinzia Sissa et al.

TRANSFUSION AND APHERESIS SCIENCE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic thrombocytopenic purpura after ChAdOx1 nCoV-19 vaccine

Hui Ping Lee et al.

Summary: This report describes a case of immune-mediated thrombotic thrombocytopenic purpura (TTP) diagnosed after administration of the ChAdOx1 nCoV-19 vaccine. Prompt treatment resulted in remission of TTP and discharge of the patient after three weeks.

BMJ CASE REPORTS (2021)

Add to Collection

Article Hematology

Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine

Syed Hamza Bin Waqar et al.

Summary: TTP, a rare hematologic threat, has been associated with COVID-19 mRNA vaccines during the COVID-19 pandemic, as seen in a case of a 69-year-old male with multiple comorbidities.

INTERNATIONAL JOURNAL OF HEMATOLOGY (2021)

Add to Collection

Article Hematology

Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine

Hannah Maayan et al.

Summary: This study presents a case series of patients who developed acquired Thrombotic Thrombocytopenic Purpura shortly after receiving the BNT162b2 vaccine. It recommends evaluating ADAMTS13 activity in patients with a history of aTTP before and after vaccination, especially with the SARS-CoV-2 vaccine. Close monitoring of patients' clinical situation and laboratory data post-vaccination is essential.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Hematology

First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination

Severine de Bruijn et al.

Summary: This case report describes a 38-year-old woman who developed de novo iTTP after receiving an mRNA-based COVID-19 vaccine. She presented with skin bruising and petechiae 2 weeks after vaccination. Treatment with plasma exchange, corticosteroids, rituximab, and caplacizumab was successful in managing her condition.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Microbiology

Renal Thrombotic Microangiopathy in Concurrent COVID-19 Vaccination and Infection

Marco De Fabritiis et al.

Summary: This case report describes a 35-year-old male who developed nephrotic proteinuria and microhematuria following the first dose of BNT162b2 COVID-19 vaccine and COVID-19 diagnosis. After high-dose steroid treatment, complete remission of proteinuria was achieved in a few weeks. The association of renal thrombotic microangiopathy with COVID-19 has been described previously, but the correlation with COVID-19 vaccine is a novel finding.

PATHOGENS (2021)

Add to Collection

Article Urology & Nephrology

Glomerular Disease in Temporal Association with SARS-CoV-2 Vaccination: A Series of 29 Cases

Tiffany N. Caza et al.

Summary: Vaccination against SARS-CoV-2 may trigger kidney diseases in susceptible individuals, but the overall incidence is low and should be closely monitored for as a potential adverse event.

KIDNEY360 (2021)

Add to Collection

Article Hematology

Vaccine-induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine-A case report

Bader Al Rawahi et al.

Summary: Vaccination with ChAdOx1 nCov-19 can lead to vaccine-induced immune thrombotic thrombocytopenia (VITT), similar to heparin-induced thrombocytopenia (HIT) but without the need for heparin. Diagnosis and treatment of VITT are crucial due to its potentially life-threatening complications.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2021)

Add to Collection

Article Immunology

Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape

John S. Tregoning et al.

Summary: The development and rollout of vaccines have brought hope for controlling the COVID-19 pandemic, with vaccines proving highly effective in preventing disease. However, challenges remain in ensuring equitable access to vaccines globally, as well as lessons to be learned for controlling pandemics in the future.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Review Immunology

COVID-19: Immunology and treatment options

Susanna Felsenstein et al.

CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Potential role of endothelial cell surface ectopic redox complexes in COVID-19 disease pathogenesis

Isabella Panfoli

CLINICAL MEDICINE (2020)

Add to Collection

Article Hematology

Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome

Elizabeth A. Middleton et al.

BLOOD (2020)

Add to Collection

Article Rheumatology

Anti-Neutrophil Extracellular Trap Antibodies and Impaired Neutrophil Extracellular Trap Degradation in Antiphospholipid Syndrome

Yu Zuo et al.

ARTHRITIS & RHEUMATOLOGY (2020)

Add to Collection

Review Immunology

Targeting the NLRP3 Inflammasome in Severe COVID-19

Tracey L. Freeman et al.

FRONTIERS IN IMMUNOLOGY (2020)

Add to Collection

Review Cell Biology

COVID-19, Renin-Angiotensin System and Endothelial Dysfunction

Razie Amraei et al.

CELLS (2020)

Add to Collection

Review Medicine, Research & Experimental

The complement system in COVID-19: friend and foe?

Anuja Java et al.

JCI INSIGHT (2020)

Add to Collection

Article Multidisciplinary Sciences

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Ugur Sahin et al.

NATURE (2020)

Add to Collection

Review Hematology

Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review

Alexander Fletcher-Sandersjoo et al.

THROMBOSIS RESEARCH (2020)

Add to Collection

Review Immunology

The good, the bad, and the opportunities of the complement system in neurodegenerative disease

Nicole D. Schartz et al.

JOURNAL OF NEUROINFLAMMATION (2020)

Add to Collection

Article Hematology

Relapse of immune-mediated thrombotic thrombocytopenic purpura following mRNA COVID-19 vaccination: a prospective cohort study

Gaetano Giuffrida et al.

HAEMATOLOGICA (2020)

Add to Collection

Review Immunology

NETosis, complement, and coagulation: a triangular relationship

Cynthia M. de Bont et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Clinical promise of next-generation complement therapeutics

Dimitrios C. Mastellos et al.

NATURE REVIEWS DRUG DISCOVERY (2019)

Add to Collection

Review Immunology

How vaccines work: immune effector mechanisms and designer vaccines

Stewart Sell

EXPERT REVIEW OF VACCINES (2019)

Add to Collection

Review Pharmacology & Pharmacy

Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases

Maria Angela Incalza et al.

VASCULAR PHARMACOLOGY (2018)

Add to Collection

Review Urology & Nephrology

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Timothy H. J. Goodship et al.

KIDNEY INTERNATIONAL (2017)

Add to Collection

Review Urology & Nephrology

Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea

Vicky Brocklebank et al.

CLINICAL KIDNEY JOURNAL (2017)

Add to Collection

Article Immunology

NETosing Neutrophils Activate Complement Both on Their Own NETs and Bacteria via Alternative and Non-alternative Pathways

Joshua Yuen et al.

FRONTIERS IN IMMUNOLOGY (2016)

Add to Collection

Review Hematology

How I treat refractory thrombotic thrombocytopenic purpura

Farzana A. Sayani et al.

BLOOD (2015)

Add to Collection

Review Medicine, General & Internal

Syndromes of Thrombotic Microangiopathy

James N. George et al.

NEW ENGLAND JOURNAL OF MEDICINE (2014)

Add to Collection

Article Genetics & Heredity

Interaction between Fibrinogen and IL-6 Genetic Variants and Associations with Cardiovascular Disease Risk in the Cardiovascular Health Study

Cara L. Carty et al.

ANNALS OF HUMAN GENETICS (2010)

Add to Collection

Article Immunology

The strength of B cell immunity in female rhesus macaques is controlled by CD8+ T cells under the influence of ovarian steroid hormones

FX Lü et al.

CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2002)

Add to Collection

© Peeref 2019-2024. All rights reserved.